Bryan Bergman, Ph.D.

Professor of Medicine

bryan bergman

Dr. Bergman is a Professor in the Division of Endocrinology, Diabetes, and Metabolism at the University of Colorado Anschutz Medical Campus. Dr. Bergman’s research investigates the relationship between muscle lipids and insulin sensitivity, and he has been continuously funded by the NIH since 2005. His laboratory focuses on two main research themes. One theme seeks to understand the relationship between skeletal muscle subcellular lipid localization and insulin resistance in humans. Specifically, his lab is investigating how the intracellular location, molecular species, and isomers of diacylglycerol and sphingolipids promote insulin resistance in humans. The current study is investigating these changes after insulin sensitizing lifestyle interventions and is funded by R01DK111559.  The second research emphasis aims to elucidate how intermuscular adipose tissue impacts skeletal muscle insulin sensitivity, muscle strength, and size in humans. This study combines muscle biopsy visits with elective surgeries to obtain intermuscular, subcutaneous, and visceral adipose tissue biopsies and is funded by R01DK118149.  Dr. Bergman’s laboratory also pursues mechanistic relationships between inter- and intra-muscular lipids and insulin sensitivity using primary muscle cell culture. This model is unique as the phenotype of donor is maintained in culture.  They are using this model to determine mechanisms underlying the relationship between localized muscle lipids and insulin sensitivity, and how the secretome of intermuscular adipose tissue promotes insulin resistance.  The overall goal of Dr. Bergman’s research is to uncover novel therapeutic targets to increase muscle insulin sensitivity, a need not bet by currently therapies, to help prevent and treat pre-diabetes and type 2 diabetes.
Dr. Bergman is also the director of the Molecular and Cellular Analysis core for the Nutrition and Obesity Research Center, and his lab runs a “Lipidomics and Mass Spetrometry core” that is directed by Dr. Karin Zemski Berry. 

Lipidomics and Mass Spectrometry Core 

Selected Publications

  1. Features of hepatic and skeletal muscle insulin resistance unique to type 1 diabetes in humans.
    Bergman BC, Howard D, Schauer IE, Maahs DM, Snell-Bergeon JK, Eckel RH, Perreault L, Rewers M.
    Journal of Clinical Endocrinology and Metabolism, 2012 Feb 22.
  2. Adiponectin dysregulation and insulin resistance in type 1 diabetes.
    Pereira RI, Snell-Bergeon JK, Erickson C, Schauer IE, Bergman BC, Rewers M, Maahs DM.
    J Clin Endocrinol Metab. 2012 Apr;97(4):E642-7. Epub 2012 Jan 25.
  3. Localisation and composition of skeletal muscle diacylglycerol predicts insulin resistance in humans.
    Bergman BC, Hunerdosse DM, Kerege A, Playdon MC, Perreault L.
    Diabetologia. 2012 Apr;55(4):1140-50. Epub 2012 Jan 15.
  4. Fenofibrate administration does not affect muscle triglyceride concentration or insulin sensitivity in humans.
    Perreault L, Bergman BC, Hunerdosse DM, Howard DJ, Eckel RH.
    Metabolism. 2011 Aug;60(8):1107-14. Epub 2011 Feb 8.
  5. Glycaemic variability is associated with coronary artery calcium in men with Type 1 diabetes: the Coronary Artery Calcification in Type 1 Diabetes study.
    Snell-Bergeon JK, Roman R, Rodbard D, Garg S, Maahs DM, Schauer IE, Bergman BC, Kinney GL, Rewers M.
    Diabet Med. 2010 Dec;27(12):1436-42. doi: 10.1111/j.1464-5491.2010.03127.x.
  6. Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: The CACTI study.
    Schauer IE, Snell-Bergeon JK, Bergman BC, Maahs DM, Kretowski A, Eckel RH, Rewers M.
    Diabetes. 2011 Jan;60(1):306-14. Epub 2010 Oct 26.
  7. Incretin action maintains insulin secretion, but not hepatic insulin action, in people with impaired fasting glucose.
    Perreault L, Man CD, Hunerdosse DM, Cobelli C, Bergman BC.
    Diabetes Res Clin Pract. 2010 Oct;90(1):87-94. Epub 2010 Aug 13.
  8. Lipoprotein subfraction cholesterol distribution is proatherogenic in women with type 1 diabetes and insulin resistance.
    Maahs DM, Hokanson JE, Wang H, Kinney GL, Snell-Bergeon JK, East A, Bergman BC, Schauer IE, Rewers M, Eckel RH.
    Diabetes. 2010 Jul;59(7):1771-9. Epub 2010 Apr 14.
  9. Altered intramuscular lipid metabolism relates to diminished insulin action in men, but not women, in progression to diabetes.
    Perreault L, Bergman BC, Hunerdosse DM, Eckel RH.
    Obesity (Silver Spring). 2010 Nov;18(11):2093-100. Epub 2010 Apr 8.
  10. Increased intramuscular lipid synthesis and low saturation relate to insulin sensitivity in endurance-trained athletes.
    Bergman BC, Perreault L, Hunerdosse DM, Koehler MC, Samek AM, Eckel RH.
    J Appl Physiol. 2010 May;108(5):1134-41. Epub 2010 Mar 18.
  11. Inflexibility in intramuscular triglyceride fractional synthesis distinguishes prediabetes from obesity in humans.
    Perreault L, Bergman BC, Hunerdosse DM, Playdon MC, Eckel RH.
    Obesity (Silver Spring). 2010 Aug;18(8):1524-31. Epub 2009 Dec 24.
  12. Intramuscular lipid metabolism in the insulin resistance of smoking.
    Bergman BC, Perreault L, Hunerdosse DM, Koehler MC, Samek AM, Eckel RH.
    Diabetes. 2009 Oct;58(10):2220-7. Epub 2009 Jul 6.

Graduate Schools
PhD, University of California at Berkeley (1999)
MS, University of California at Berkeley (1996)

Undergraduate Schools
BS, University of Wyoming (1993)

Postdoctoral Fellowship
Post-Doc, University of Colorado Health Sciences Center (1999-2003)

Amanda Garfield
Amanda Garfield
Professional Research Assistant

kathleen harrison
Kathleen Harrison, PhD
Senior Research Associate

darcy kahn

Darcy Kahn
Pre-Doctoral Trainee

Emily Macias
Emily Macias
Professional Research Assistant

Simona Zarini, PhD
Simona Zarini, PhD

Karin Zemski Berry, PhD
Karin Zemski Berry, PhD
Senior Instructor